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Abstract
Tissue factor (TF) is the primary activator of the coagulation cascade. Under normal conditions,
endothelial cells (ECs) and blood cells, such as monocytes, do not express TF. However, bacterial
lipopolysaccharide (LPS) induces TF expression in monocytes and this leads to disseminated
intravascular coagulation during endotoxemia and sepsis. A variety of stimuli induce TF
expression in ECs in vitro, although it is unclear how much TF is expressed by the endothelium in
vivo. LPS induction of TF gene expression in monocytic cells and ECs is mediated by various
intracellular signaling pathways and the transcription factors NF-κB, AP-1 and Egr-1. In contrast,
vascular endothelial cell growth factor (VEGF) induces TF gene expression in ECs via the
transcription factors NFAT and Egr-1. Similarly, oxidized phospholipids (oxPAPC) induce TF
expression in ECs and possibly monocytes via NFAT and Egr-1. Thromboxane (TX) A2 can now
be added to the list of stimuli that induce TF gene expression in both monocytes and ECs.
Interestingly, inhibition of the TX-prostanoid (TP) receptor also reduces TF expression in ECs
stimulated with tumor necrosis factor (TNF)-α and monocytes stimulated with LPS, which
suggests that TP receptor antagonist may be useful in reducing pathologic TF expression in the
vasculature.
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TF is a transmembrane protein that functions as the primary initiator of the coagulation
cascade1. Upon vascular damage, TF surrounding the vasculature comes into contact with
blood. This leads to the formation of the TF:FVIIa complex that activates both FX and FIX,
with subsequent thrombin generation, fibrin deposition and activation of platelets1. TF is
constitutively expressed by cells within and surrounding the blood vessel wall, such as
pericytes and adventitial fibroblasts2,3. It has been proposed that TF expressed by these cell
types forms a hemostatic envelope that limits bleeding after vessel injury2. However, in
pathologic conditions like sepsis, TF is also expressed by vascular cells, such as monocytes
and ECs4. This expression can lead to disseminated intravascular coagulation (DIC) and
thrombosis. TF expression by monocytes may be part of the innate immune response and is
probably an attempt by the host to reduce the spread of pathogenic organisms. In
atherosclerosis, TF is expressed by several cell types within atherosclerotic plaques,
including macrophage-derived foam cells 5. After plaque rupture, TF likely contributes to
the formation of a thrombus.
TF expression in monocytes and ECs
Under normal conditions TF is not expressed by circulating blood cells2. However, one
study found low levels of TF expression in a few CD14-positive monocytes6. Stimulation of
monocytes and monocytic cells with LPS induces TF expression in vitro and in vivo2,6–9.
Furthermore, we and others have shown that TF expression by hematopoietic cells
contributes to the activation of coagulation in endotoxemic mice10,11. In vitro studies
demonstrated that a variety of agonists, including LPS, IL-1β, TNF-α, thrombin and VEGF,
induce TF expression on ECs12–26. In contrast, only a limited number of studies have
reported TF expression by ECs in vivo. One study found co-localization of TF and the EC
marker von Willebrand factor within the splenic microvasculature of septic baboons but not
in ECs of pulmonary vessels4. Another study found TF protein on ECs in LPS treated mice
and rabbits27,28. More recently, TF protein was observed on ECs at branch points of the
aorta of septic baboons29. TF protein co-localized with fibrin deposition, suggesting that it
was functional29. However, TF present on ECs was restricted to granular structures some of
which were also positive for the leukocyte marker P-selectin glycoprotein ligand-1
(PSGL-1)29. This suggests that leukocyte-derived microparticles may deliver TF to activated
ECs in vivo. In contrast to these studies, we and others did not detect TF expression by ECs
in LPS treated mice, rats, and rabbits30–33. These different results may be caused by the
relative sensitivity of the various techniques used to detect TF expression. Furthermore, it is
possible that TF expression on ECs contributes to signaling rather than activation of
coagulation. We analyzed the effect of EC-specific deletion of the TF gene on the activation
of coagulation in mouse models of endotoxemia and sickle cell disease. We found that a
deficiency of TF in ECs did not decrease the activation of coagulation in either model34,35.
However, in the sickle cell disease model we found a reduction of IL-6 expression35. Similar
results were observed with a FXa inhibitor or protease-activated receptor (PAR)-2
deficiency in non-hematopoietic cells suggesting that TF on ECs contributes to the induction
of IL-6 expression via FXa activation of PAR-2.
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Induction of TF gene expression in monocytes
i) LPS
The THP-1 cell line has been used as a model to study the regulation of TF gene expression
in monocytes. These cells are derived from an acute human monocytic leukemia. LPS
stimulation of THP-1 increases the rate of TF gene transcription, TF mRNA and TF protein.
The human TF promoter contains a NF-κB site and two AP-1 sites in a distal region (Figure
1)36. In addition, the proximal region of the promoter contains two Sp1 sites (−172 to −112)
and three overlapping Sp1/Egr-1 sites (−111 to +14) (Figure 1)37. The proximal region of
the promoter (−170 to −59 bp) is required for basal expression38.
An LPS response element (LRE) in the human TF promoter was identified by analyzing a
series of plasmids containing different lengths of the promoter cloned upstream of the
luciferase reporter gene. This element spans 56-bp (−227 to −172) and contains a NF-κB
site and two AP-1 sites36. The NF-κB site is essential for full functionality of the LRE36.
Interestingly, the NF-κB site does not match the κB consensus sequence due to a C instead
of a G at position 139 and binds c-Rel-p65 heterodimers and not the prototypic p50-p65
heterodimers40. It was found that the transcriptional activation of the TF gene involves
functional interactions between c-fos/c-jun and c-Rel-p65 heterodimers14. In addition, LPS
induction of the TF gene was sensitive to nucleotide spacing between the proximal AP-1 and
κB sites. Conservation of this 15-bp spacing in the human, murine, and porcine promoters
may be required for physical association between c-fos/c-jun and c-Rel/p65 heterodimers41.
Alternatively, the conserved spacing and defined DNA bending between the AP-1 and κB
sites may be important for allowing the interaction of c-fos/c-jun and c-Rel/p65 with the
TATA box binding protein and transcription factor IIB within the basal transcriptional
machinery41. Additional studies showed that Egr-1 is required for maximal LPS induction of
the TF promoter42. Mutation of the Egr-1 sites in the TF promoter or inhibition of the ERK
1/2 pathway, which induces Egr-1 gene expression, reduced the level of LPS induction of
TF gene expression42.
ii) Oxidized low-density lipoprotein (oxLDL)
We recently showed that oxLDL, but not LDL, increased TF expression in THP-1 and
human peripheral blood mononuclear cells (PBMCs)43. Preincubation of the cells with a
TLR-4 inhibitor (CLI-095) or simvastatin reduced the induction of TF expression43. We are
currently analyzing the different signaling pathways and transcription factors that mediate
oxLDL induction of TF expression.
Induction of TF gene expression in ECs
i) LPS, IL-1β and TNF-α
We found that LPS induction of TF gene expression in ECs was mediated by the LRE and
Egr-1 sites (Figure 1), indicating that a common mechanism regulates TF gene expression in
both human monocytes and ECs14,42. Furthermore, TNF-α and IL-1β also activated AP-1
and NF-κB in human umbilical vein ECs (HUVECs)14. A study that subjected human
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pulmonary artery ECs to inhibitors of several intracellular signaling pathways demonstrated
a critical role for protein kinase C (PKC) and for p38 in the induction of TF expression44.
ii) CD40L
CD40L induces TF expression through a variety of pathways in ECs, ultimately involving
the transcription factors AP-1, NF-κB and Egr-1 that all appear to be necessary in order to
achieve a maximal response (Figure 1)19–22.
iii) Antiphospholipid antibodies
Antiphospholipid syndrome is an autoimmune disease caused by antiphospholipid
antibodies. Patients are hypercoagulable particularly during pregnancy45,46. Anti-
phospholipid antibodies have been shown to induce TF expression on HUVECs through an
unknown receptor but involving the NF-κB and p38 intracellular pathways (Figure 1)24.
Similar results were observed using PBMCs47. Induction of TF expression in monocytes and
ECs may explain the prothrombotic state caused by these antibodies and it may lead to the
development of more directed antithrombotic/anti-inflammatory therapy in these patients,
for example by inhibition of p38 (Figure 1).
iv) VEGF
VEGF has been shown to induce TF gene expression in HUVECs via two distinct pathways.
First, it triggers NFAT dephosphorylation by calcineurin, which allows nuclear translocation
of NFAT, binding to a site in the TF promoter (−197 to −183) and induction of TF gene
expression16. There is some evidence that it also increases the transcriptional activity of
AP-116,48. Secondly, VEGF induces TF gene expression via a PKC-dependent pathway that
leads to activation of ERK 1/2 and Egr-1 gene expression17. Importantly, NFAT and Egr-1
synergistically cooperate in VEGF induction of the TF promoter (Figure 1)49.
v) oxPAPC
OxLDL and oxPAPC induce TF expression in HUVECs50. Interestingly, oxPAPC induction
of TF gene expression involved both NFAT and Egr-1 in a similar manner to VEGF (Figure
1)18.
vi) Shear stress
Two studies have reported that induction of the TF gene in ECs by laminar shear stress was
mediated by a GC-rich region (−111 to +14) containing three copies each of the Egr-1 and
Sp1 sites15,51. These Egr-1 and Sp1 binding sites are overlapping which precludes binding
of both transcription factors at the same time15. One study concluded that the induction was
mediated by modifying Sp1 bound to the promoter51. However, a second study concluded
that shear stress induced the expression of Egr-1 and that this leads to increased TF gene
expression (Figure 1)15, which is a more plausible mechanism.
vii) Indolic uremic solutes
Uremic solutes are increased in patients with chronic kidney disease and could contribute to
their prothrombotic phenotype and high cardiovascular mortality. Recently, a study reported
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that the indolic uremic solutes indoxyl sulfate and indole-3-acetic acid induce TF expression
in HUVECs23. Interestingly, this induction was mediated by the aryl hydrocarbon receptor
(AHR) (Figure 1)23. After activation, AHR translocates to the nucleus and acts as a
transcription factor. However, there is no consensus sequence for AHR binding in the TF
promoter, although it may bind to a non-consensus sequence. Alternatively, AHR may
enhance signaling pathways or interact with transcription factors that regulate TF gene
expression52–54.
A summary of the different intracellular signaling pathways and transcription factors
involved in the induction of TF gene expression in monocytes and ECs is shown in Table 1.
TXA2 and TF expression in monocytes and ECs
The eicosanoid TXA2 is a proinflammatory mediator. It activates a variety of cell types,
including monocytes and ECs, by binding to the TP receptor55. A paper in this issue of
Vascular Pharmacology found that a TP receptor agonist (U46619) induced TF expression
in ECs25. A previous study showed that U46619 induces MCP-1 expression in ECs56. The
TP receptor activates a PKC dependent pathway that leads to the activation of AP-1 and NF-
κB56. In a mouse model of microcirculatory dysfunction in the liver, TNF-α induced
leukocyte adhesion was significantly reduced by administration of a TXA2 synthase
inhibitor (OKY-046) and in TP receptor knockout mice, suggesting TP receptor signaling
may promote hepatic dysfunction elicited by TNF-α57. The phenotype of TP deficient mice
was more pronounced than that of TX synthase deficient mice suggesting that ligands other
than TXA2 may activate the TP receptor55. This study indicated that TXA2 stimulation of
the TP receptor contributes to the effects of TNF-α in vivo. Interestingly, Del Turco and
colleagues found that inhibition of the TP receptor reduced TNF-α induction of TF
expression in ECs25. Importantly, TXA2 production is enhanced in HUVECs by TNF-α or
platelet-activating factor (PAF) stimulation58–60. However, Del Turco and colleagues
concluded that the reduction of TNF-α induction of TF expression by blocking the TP
receptor was not due to the production of TXA2 or prostanoids by the ECs since they did not
observe any effect after treating the cells with acetylsalicylic acid (ASA) or indomethacin25.
One concern is that levels of the TXA2 metabolic product TXB2 were only measured at 24
hours. Moreover, the cells may express other ligands that activate the TP receptor55.
An alternative explanation for the effect of the TP antagonist on TNF-α is that the activated
cells express TXA2 and this activates the TP receptor and enhances the induction of TF
expression (Figure 2). If this notion is correct one would predict that the effect of the TP
antagonist would be more pronounced at later times. Unfortunately, Del Turco and
colleague only analyzed TF expression at 6 hours25. Another study found that TNF-α or
PAF induction of ICAM-1 expression in ECs was decreased with a TXA2 synthesis inhibitor
(DP-1904)58. Similarly, treatment of ECs with a TP receptor antagonist (SQ29 548 or
BAYu3405) reduced TNF-α or PAF induction of ICAM-1 and MCP-1 expression56,59.
Taken together, these results suggest that TNF-α and PAF stimulation of ECs leads to
production of TXA2 that is secreted and then activates intracellular pathways through the TP
receptor (Figure 2).
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Consistent with the above results in ECs, TF expression is reduced in LPS stimulated human
monocytes by a TP receptor antagonist (SQ29 548) and by indobufen, a cyclooxygenase
(COX)-1/2 inhibitor, which decreases TXA2 production61,62. Treatment with ASA, a
COX-1 inhibitor, does not reduce TF expression, suggesting that COX-2 metabolites, such
as TXA2, are regulators of TF expression61. Indobufen also led to reduced ERK 1/2
phosphorylation, suggesting an involvement of this pathway in induction of TF
expression61. In another study examining the effect of a variety of inhibitors on the LPS
induced monocyte TF expression in human whole blood, the TP receptor and PAF receptor
were shown to be necessary for full induction of TF activity63.
Conclusions
TF is a cellular receptor that initiates blood coagulation. It is constitutively expressed in
some extravascular cell types and its expression is inducible in several vascular cell types,
including monocytes and ECs. Further studies are needed to clarify the exact mechanism of
TNF-α induced TP receptor activation and to assess the effects of this activation in different
cell types and in vivo in different pathologic settings. The observation that the TP receptor is
an important inducer of TF expression in ECs is intriguing because antagonization of the TP
receptor may represent a new treatment of acute and chronic inflammatory conditions that
involve TF expression, such as sepsis and atherosclerosis. Terutroban, the TP receptor
antagonist used by Del Turco and colleagues has already been compared to ASA in a
randomized controlled trial (PERFORM)64 on patients with recent ischemic stroke or
transient ischemic attacks. No significant difference was found for the primary endpoint
which was a composite of fatal or non-fatal ischemic stroke, fatal or non-fatal myocardial
infarction, or other vascular death. One possible explanation for the negative result, with the
notion that a major effect of the drug is the inhibition of TF expression, is that there is little
benefit to be gained after the ischemic event. It would be interesting, however, to see TP
receptor antagonists evaluated in the primary prevention of stroke or coronary artery disease
and in the treatment of DIC or other thrombotic conditions associated with monocyte TF
expression.
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Induction of the human tissue factor (TF) promoter in endothelial cells. Shown are
intracellular signaling pathways, transcription factors and DNA binding sites that regulate
TF gene expression in response to different agonists. Receptor (R), oxidized phospholipids
(oxPAPC), antiphospholipid antibody (APL-ab), aryl hydrocarbon receptor (AHR),
thromboxane A2 (TXA2), thrombin (FIIa), indoxylsulfate (IS), vascular endothelial growth
factor (VEGF), protease-activated receptor 1 (PAR-1).
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Proposed mechanism by which the TP receptor (TP-R) contributes to gene expression in
endothelial cells. TP-R can directly be activated by TXA2 or receptor agonists and induce
the expression of tissue factor (TF), ICAM-1 and MCP-1 In addition, the presence of the
TP-R enhances TNF-α and PAF induction of gene expression by increasing TXA2
expression by TXA2-synthase. TNF-α receptor (TNF-R), PAF receptor (PAF-R).
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